Combined Effect of Reflexology and GS on Insomnia Vesomotor Symptoms and QOL in Post-menopausal Women

Combined Effect of Reflexology and General Stretching on Insomnia Vesomotor Symptoms and Quality of Life in Post-menopausal Women

The purpose of this study is to assess how reflexology and general stretching affect postmenopausal women's quality of life, vasomotor symptoms, and insomnia. Hormonal changes in postmenopausal women frequently result in hot flashes, sleep difficulties, and a general reduction in quality of life. Although non-pharmacological treatments like stretching and reflexology have demonstrated promise in treating these symptoms on their own, little study has evaluated how well they work together.

Purposive sampling was used to choose postmenopausal women between the ages of 45 and 60 for a randomized controlled experiment. Participants were divided into two groups at random: the group participating in the experiment received generalized stretching exercises and reflexology, whereas the control group only received stretching or routine care. Three sessions a week for six weeks was the duration of the intervention. Standardized instruments such as the Menopause Ratings Scale (MRS) for vasomotor complaints, the severity index for insomnia (ISI), and the menu menopausal particular aspects of life and post-intervention evaluations were used to measure outcomes. The effectiveness of the measures was then compared."

Inclusion Criteria:

• Postmenopausal women aged between 45 and 60 years
• Women experiencing insomnia, vasomotor symptoms (e.g., hot flashes), and reduced quality of life
• Women who are at least 12 months amenorrheic
• Willing to participate and provide informed consent
• Physically able to perform stretching exercises

Exclusion Criteria:

• Women on hormone replacement therapy or other medications affecting sleep or menopause symptoms
• History of recent surgery or musculoskeletal injuries preventing physical activity
• Diagnosed psychiatric or neurological disorders
• Severe systemic illnesses (e.g., uncontrolled diabetes, cardiovascular diseases)
• Participation in another clinical trial or intervention in the last 3 months